Finnegan Stone
London,United Kingdom
Summary
Detail-oriented professional with expertise in market access strategies, complex data analysis and health economic modelling. Committed to leveraging problem-solving skills to drive strategic insights and enhance business outcomes. Offering a strong analytical background with solid problem-solving and critical thinking skills.
Overview
6
6
years of professional experience
2025
2025
years of post-secondary education
Work history
Analyst - Market Access and Pricing Strategy
Dolon Ltd
London
2024.10 - Current
- Contributed to team projects by providing key analytic insights on multiple projects, driving forward workstreams on several projects.
- Maintained in-depth knowledge of industry advancements and emerging software tools to improve analytical workflow.
- Gained project management experience and facilitated the delivery of workshops and the external delivery of projects.
- Contributed to business development, facilitating over £500,000 of business won within H1 2025.
Health Economics Intern
MSD
2024.06 - 2024.09
- Planned, created and executed modelling, budget impact analysis and associated literature review to evaluate the cost-effectiveness of Pembrolizumab for early-stage triple-negative breast cancer.
- Supported the preparation of regulatory documents and HTA submissions to NICE and SMC, contributing towards successful reimbursement outcomes for Pembrolizumab indication expansions.
Research Assistant
University of Cambridge
2021.09 - 2022.08
- Researched novel chemotherapeutic co-treatments.
- Carried out quantitative and qualitative data analysis researching the mRNA response to Doxorubicin and Trazodone exposure to aid projects researching Trazodone's effect in reducing cancer metastasis.
- Presented bi-weekly seminars to cultivate interest in mRNA therapeutics and their potential role in cancer treatment.
Marketing Intern
GSK
2019.06 - 2019.07
- Attended internal strategic discussions on pricing and distribution complexities of key treatment drugs within EMEA.
- Gained insight into some of the manufacturing challenges along with the clinical trial process and the hurdles involved in getting Juluca (dolutegravir and rilpivirine) to market.
Education
MSc - International Health Policy
London School of Economics and Political Science (LSE)
London, London October 2023 - 2024.06
BSc - Biochemistry (Industrial)
University of Leeds
Leeds, United KingdomSkills
- VBA programming
- Advanced excel proficiency
- Microsoft PowerPoint
- Microsoft Word
- Global data (POLI)
- STATA
- Market access strategies
- Problem-solving
- Data collection and analysis
Timeline
Analyst - Market Access and Pricing Strategy
Dolon Ltd
2024.10 - Current
Health Economics Intern
MSD
2024.06 - 2024.09
Research Assistant
University of Cambridge
2021.09 - 2022.08
Marketing Intern
GSK
2019.06 - 2019.07
MSc - International Health Policy
London School of Economics and Political Science (LSE)
October 2023 - 2024.06
BSc - Biochemistry (Industrial)
University of Leeds